Inhibition of complement pathway activation with Pozelimab, a fully human antibody to complement component C5.

Inhibition of complement pathway activation with Pozelimab, a fully human antibody to complement component C5.

Complement is a key component of the innate immune system. Inappropriate complement activation underlies the pathophysiology of a variety of diseases. Complement component 5 (C5) is a validated therapeutic target for complement-mediated diseases, but the development of new therapeutics has been limi...

Full description

Bibliographic Details
Main Authors: Adrianna Latuszek, Yashu Liu, Olav Olsen, Randi Foster, Marc Cao, Irena Lovric, Ming Yuan, Nina Liu, Henry Chen, Qian Zhang, Hui Xiao, Carola Springer, George Ehrlich, Vishal Kamat, Ashique Rafique, Ying Hu, Pamela Krueger, Tammy Huang, William Poueymirou, Robert Babb, Michael P Rosconi, Marc W Retter, Gang Chen, Lori Morton, Brian Zambrowicz, Jingtai Cao, Carmelo Romano, William C Olson
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2020-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0231892

Internet

https://doi.org/10.1371/journal.pone.0231892

Similar Items